H
Houda Bahig
Researcher at Université de Montréal
Publications - 112
Citations - 1388
Houda Bahig is an academic researcher from Université de Montréal. The author has contributed to research in topics: Medicine & Radiation therapy. The author has an hindex of 16, co-authored 83 publications receiving 782 citations. Previous affiliations of Houda Bahig include Hôpital Maisonneuve-Rosemont & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
A Portrait of Current Radiation Oncology Twitter Influencers.
TL;DR: The fact that some influencers had a low H-index supports that a high academic profile as measured by traditional metrics is not necessary to have a voice in the Twitter radiation oncology community.
Journal ArticleDOI
Partial kilovoltage cone beam computed tomography, complete kilovoltage cone beam computed tomography, and electronic portal images for breast radiation therapy: A dose-comparison study
Houda Bahig,Étienne Roussin,Michael A. Yassa,P. Vavassis,Céline Lemaire,Laurie Archambault,David H.A. Nguyen +6 more
TL;DR: Use of CBCT was associated with decreased dose to ipsilateral breast and increased dose to all OARs compared with EPI, suggesting significant dose reduction can be achieved with the use of partial CBCT, while generally maintaining image quality.
Journal ArticleDOI
Phase II study of de-intensified intensity-modulated radiotherapy and concurrent carboplatin/5-fluorouracil in lateralized p16-associated oropharyngeal carcinoma.
Houda Bahig,Louise Lambert,Edith Filion,Denis Soulières,Louis Guertin,Tareck Ayad,Apostolos Christopoulos,Eric Bissada,M. Alizadeh,Manon Bélair,Phuc Felix Nguyen-Tan +10 more
TL;DR: To assess cancer control and patient‐reported outcomes (PROs) after de‐intensified intensity‐modulated radiotherapy (IMRT) in lateralized p16‐associated oropharyngeal cancer (p16‐OPC).
Journal ArticleDOI
Initial analyses of a phase I/II trial of durvalumab (D) plus tremelimumab (T) and stereotactic body radiotherapy (SBRT) for oligometastatic head and neck carcinoma.
Houda Bahig,Francine Aubin,Phuc Felix Nguyen-Tan,Denis Souliere,David A. Palma,Danielle Charpentier,Brock Debenham,Rahima Jamal,K. Sultanem,Olivier Ballivy,Edith Filion,Philip Wong +11 more
TL;DR: The once-weekly PD-1/PD-L1 +/- CTLA-4 blockade in head-and-neck carcinoma (HNSCC) has shown signs of clinical activity and SBRT aims to reduce tumor burden and perhaps be immune-stimulatory.
Journal ArticleDOI
Oligometastases: Emerging Evidence.
TL;DR: A review of randomized evidence evaluating metastasis-directed therapy in patients with oligometastatic disease is presented in this paper , where the authors discuss the challenges in defining the disease, summarize the randomized evidence, provide context for the difficulty in generating randomized evidence and examine ongoing phase III studies.